![Alicia Secor](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alicia Secor
Direktor/Vorstandsmitglied bei
ZEVRA THERAPEUTICS, INC.
Vermögen: - $ am 30.06.2026
Profil
Alicia Secor is President, Chief Executive Officer & Director at Paratus Sciences Corp.
since 2026.
Ms. Secor is Director at Foundation For Prader-Willi Research, Inc. since 2016.
Ms. Secor is Independent Director at Zevra Therapeutics, Inc. since 2025.
Former roles include President, Chief Executive Officer & Director at Atalanta Therapeutics, Inc. from 2019 to 2025; President, Chief Executive Officer & Director at Catalent JNP, Inc. from 2016 to 2018; Independent Non-Executive Director at Orchard Therapeutics Plc from 2018 to 2024; Independent Director at G1 Therapeutics, Inc. from 2021 to 2024; Independent Non-Executive Director at GW Pharmaceuticals Ltd. from 2017 to 2021; Chief Commercial Officer at Zafgen, Inc. from 2014 to 2016; Chief Operating Officer & Senior Vice President at Synageva BioPharma Corp.
in 2013; Vice President & GM-Metabolic Diseases at Genzyme Corp.
from 1998 to 2013; Director at.
Orchard Therapeutics (Europe) Ltd. Education includes undergraduate degree from the University of New Hampshire and an MBA from D'Amore-Mckim School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 04.06.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
Aktive Positionen von Alicia Secor
| Unternehmen | Position | Beginn |
|---|---|---|
| ZEVRA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 02.12.2025 |
Foundation For Prader-Willi Research, Inc.
 Foundation For Prader-Willi Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Foundation For Prader-Willi Research, Inc. is a nonprofit public charity established in 2003 by parents and advocates dedicated to advancing research and therapeutic development to eliminate the challenges of Prader-Willi syndrome (PWS), a rare and complex genetic disorder characterized by obesity, cognitive impairments, behavioral difficulties, and hormonal deficiencies. The private company is based in Walnut. The organization improves the health and quality of life of individuals with PWS through grant programs, translational research, and the development of research tools such as cellular and animal models, biobanks, and data-sharing platforms. It supports collaborative efforts including the Prader-Willi Syndrome Clinical Trial Consortium, manages an international patient registry, funds and coordinates research projects across genetics, neurobiology, endocrinology, behavior, gene therapy, and clinical trials, and provides resources for families and caregivers. The foundation promotes community involvement through advocacy, fundraising, and awareness events, and encourages planned giving to sustain research efforts. | Direktor/Vorstandsmitglied | 01.11.2016 |
Paratus Sciences Corp.
 Paratus Sciences Corp. BiotechnologyHealth Technology Operates as a biotechnology company | Vorstandsvorsitzender | 22.04.2026 |
Ehemalige bekannte Positionen von Alicia Secor
| Unternehmen | Position | Ende |
|---|---|---|
Atalanta Therapeutics, Inc.
 Atalanta Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops RNA interference based therapeutics to treat neurodegenerative diseases | Vorstandsvorsitzender | 18.06.2025 |
| G1 THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 18.09.2024 |
| ORCHARD THERAPEUTICS PLC | Direktor/Vorstandsmitglied | 24.01.2024 |
| GW PHARMACEUTICALS PLC | Direktor/Vorstandsmitglied | 05.05.2021 |
| JUNIPER PHARMACEUTICALS INC | Vorstandsvorsitzender | 14.08.2018 |
Ausbildung von Alicia Secor
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
82
Beziehungen ersten Grades
14
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 14 |
|---|---|
Catalent JNP, Inc.
 Catalent JNP, Inc. Miscellaneous Commercial ServicesCommercial Services Specializes in research and development of drugs & therapeutics | Commercial Services |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
Zevra Therapeutics, Inc.
 Zevra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets proprietary prodrugs | Health Technology |
GW Pharmaceuticals Ltd.
 GW Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and markets novel therapeutics | Health Technology |
University of New Hampshire
 University of New Hampshire Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
D'Amore-Mckim School of Business
 D'Amore-Mckim School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Develops and manufactures biopharmaceutical products | Health Technology |
G1 Therapeutics, Inc.
 G1 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cancer treatment | Health Technology |
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Researches on transformative gene therapies | Health Technology |
Foundation For Prader-Willi Research, Inc.
Foundation For Prader-Willi Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Foundation For Prader-Willi Research, Inc. is a nonprofit public charity established in 2003 by parents and advocates dedicated to advancing research and therapeutic development to eliminate the challenges of Prader-Willi syndrome (PWS), a rare and complex genetic disorder characterized by obesity, cognitive impairments, behavioral difficulties, and hormonal deficiencies. The private company is based in Walnut. The organization improves the health and quality of life of individuals with PWS through grant programs, translational research, and the development of research tools such as cellular and animal models, biobanks, and data-sharing platforms. It supports collaborative efforts including the Prader-Willi Syndrome Clinical Trial Consortium, manages an international patient registry, funds and coordinates research projects across genetics, neurobiology, endocrinology, behavior, gene therapy, and clinical trials, and provides resources for families and caregivers. The foundation promotes community involvement through advocacy, fundraising, and awareness events, and encourages planned giving to sustain research efforts. | Commercial Services |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc BiotechnologyHealth Technology Engages in research and advancements of gene therapy to develop potential cures for genetic & other severe diseases | Health Technology |
Atalanta Therapeutics, Inc.
Atalanta Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops RNA interference based therapeutics to treat neurodegenerative diseases | Commercial Services |
Paratus Sciences Corp.
Paratus Sciences Corp. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
